文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

TRBC1-CAR T细胞疗法治疗外周T细胞淋巴瘤:一项1/2期试验

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.
PubMed 文献 · Nat Med · 2024-11-11

LibraT1是一项正在进行中的多中心、国际、单臂1/2期研究,评估靶向TRBC1的自体CAR T细胞(AUTO4)治疗复发/难治性TRBC1阳性外周T细胞淋巴瘤的安全性和耐受性。前10例患者剂量递增的非预设中期分析显示,1/10例发生3级细胞因子释放综合征,4/10例可评估患者达到完全代谢缓解,其中2例缓解持续超过1年。

要点

  • AUTO4输注后严重免疫毒性发生率低,10例中1例发生3级细胞因子释放综合征。
  • 10例可评估患者中4例达到完全代谢缓解,其中2例缓解持续超过1年。
  • 外周血未检测到循环CAR T细胞,但淋巴结活检样本中可检测到CAR T细胞,提示归巢至肿瘤部位。

核心结论

  • AUTO4在复发/难治性TRBC1阳性外周T细胞淋巴瘤中严重免疫毒性发生率低,部分患者获得持久完全代谢缓解,结果支持继续探索TRBC1靶向治疗。

研究设计与样本

  • LibraT1是一项正在进行中的多中心、国际、单臂1/2期研究,评估靶向TRBC1的自体CAR T细胞(AUTO4)治疗复发/难治性TRBC1阳性外周T细胞淋巴瘤。
  • 主要目标为评估AUTO4输注的安全性和耐受性,关键次要终点包括疗效、CAR T细胞扩增和持续性。
  • 本文报告前10例患者剂量递增部分的非预设中期分析结果。

主要发现

  • 10例患者中1例发生3级细胞因子释放综合征。
  • 10例可评估患者中4例达到完全代谢缓解,其中2例缓解持续超过1年。
  • 外周血未检测到循环CAR T细胞,但原发病灶部位的淋巴结活检样本中可检测到CAR T细胞,提示CAR T细胞归巢至肿瘤部位。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本文报告的是前10例患者剂量递增部分的非预设中期分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens that discriminate malignant from normal T cells, thus avoiding severe immunosuppression consequent to depletion of the entire T cell compartment. We recently described a targeting strategy based on the mutually exclusive expression of T cell antigen receptor beta-chain constant domain (TRBC) 1 and 2. Selective targeting of the T cell antigen receptor beta-chain expressed by the (clonal) malignancy spares normal T cells expressing the other chain. The LibraT1 study is an ongoing, multicenter, international, single-arm phase 1/2 study of TRBC1-directed autologous chimeric antigen receptor (CAR) T cells (AUTO4) in relapsed/refractory TRBC1-positive PTCL. Primary objectives were assessment of safety and tolerability of AUTO4 infusion. Key secondary endpoints included efficacy, CAR T cell expansion and persistence. Here we describe the findings from dose escalation in LibraT1 in the first ten patients, in a non-prespecified interim analysis. AUTO4 resulted in low frequency of severe immunotoxicity, with one of ten patients developing grade 3 cytokine release syndrome. Complete metabolic response was observed in four of ten evaluable patients, with remissions being durable beyond 1 year in two patients. While an absence of circulating CAR T cells was observed, CAR T cells were readily detected in lymph node biopsy samples from sites of original disease suggesting homing to tumor sites. These results support the continuing exploration of TRBC1 targeting in PTCL. ClinicalTrials.gov registration: NCT03590574 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Cwynarski K, Iacoboni G, Tholouli E, et al. TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial. Nat Med. 2024. PMID: 39528665. doi:10.1038/s41591-024-03326-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。